Quarterly Updates30 Apr 2026, 04:09 pm
Dr Lal PathLabs Q4 FY26 Revenue up 16.6% to
AI Summary
Dr. Lal PathLabs Limited announced its consolidated financial results for Q4 FY26. The company reported a revenue of ₹703 Cr, marking a 16.6% growth. EBITDA for the quarter increased by 10.5% with a margin of 26.6%, while Profit After Tax (PAT) was ₹132 Cr, achieving an 18.8% margin. The board also declared a final dividend of 40%, equivalent to ₹4 per share. As of March 31, 2026, the company held ₹1,526 Cr in cash and cash equivalents. Dr. Lal PathLabs operates an extensive network across India, including 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points, serving individual patients, hospitals, and corporate clients.
Key Highlights
- Q4 FY26 consolidated revenue grew 16.6% to ₹703 Cr.
- EBITDA for Q4 FY26 increased 10.5% with a 26.6% margin.
- PAT for Q4 FY26 was ₹132 Cr, achieving an 18.8% margin.
- Company declared a final dividend of ₹4 per share (40%).
- Cash and cash equivalents stood at ₹1,526 Cr as of March 31, 2026.